Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: different dose response patterns to virus surface proteins VP7 and VP4

Clark, H Fred; Lawley, Diane; Shrager, Dorothy; Jean-Guillaume, Danielle; Offit, Paul A.; Whang, Soo Yeon; Eiden, Joseph; Bennett, Philips S; Kaplan, Karen M.; Shaw, Alan

doi:10.1097/01.inf.0000115503.55212.bf

Cited by 18 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high mortality rate in developing countries and the heavy social and economical burden in industrialized countries due to RV infections underline the need for the development of an efficient vaccine. Every candidate RV vaccine that has been developed to date has consisted of orally delivered, live attenuated RV strains or reassortants (8,9,14,20,36,54,56). Most of these vaccines confer significant protection against severe diarrhea but only limited protection against RV infection or mild symptoms.…”

mentioning

confidence: 99%

Rectal Immunization with Rotavirus Virus-Like Particles Induces Systemic and Mucosal Humoral Immune Responses and Protects Mice against Rotavirus Infection

Parez

Fourgeux

Mohamed

et al. 2006

J Virol

View full text Add to dashboard Cite

To evaluate whether the rectal route of immunization may be used to provide appropriate protection against enteric pathogens such as rotaviruses (RV), we studied the antibody response and the protection induced by rectal immunization of mice with RV virus-like particles (VLP). For this purpose, 6-week-old BALBc mice were rectally immunized twice with RV 8-2/6/7-VLP derived from the bovine RV RF81 strain either alone or combined with various adjuvants including four toxins [cholera toxin (CT) and three attenuated Escherichia coli-derived heat-labile toxins (LTs), LT(R192G), LT(R72), and LT ( Rotaviruses (RV) are the leading cause of viral gastroenteritis in young children worldwide and are responsible for more than 500,000 deaths per year in developing countries (40). The high mortality rate in developing countries and the heavy social and economical burden in industrialized countries due to RV infections underline the need for the development of an efficient vaccine. Every candidate RV vaccine that has been developed to date has consisted of orally delivered, live attenuated RV strains or reassortants (8,9,14,20,36,54,56). Most of these vaccines confer significant protection against severe diarrhea but only limited protection against RV infection or mild symptoms. Moreover, live vaccines can be associated with various adverse effects, intussusception being the most severe (33). Thus, the development of new safe vaccine strategies based on nonliving RV should be considered.Virus-like particles (VLP) are nonreplicating structures that mimic virus counterparts in morphology and immunogenicity and could be safe and efficient vaccine candidates. Parenteral immunization with RV VLP has been shown to induce immunogenicity and protection in animal models, particularly in the mouse model (7,11,30). However, RV is commonly transmitted via the fecal-oral route and infects intestinal epithelial cells. Thus, vaccine strategies inducing effective intestinal mucosal immunity responses should be suitable against this pathogen and need to be assessed. RV VLP can be delivered via various mucosal routes of administration in order to induce mucosal effectors. When delivered via the oral route, which is common and handy for vaccine administration, RV VLP induce weak immune responses and do not protect against infection (3, 49). When administered by the nasal route, RV VLP efficiently induce both local and systemic specific immune responses in mice (6,29,34,35) and gnotobiotic pigs (21).

show abstract

mentioning

confidence: 99%

Rectal Immunization with Rotavirus Virus-Like Particles Induces Systemic and Mucosal Humoral Immune Responses and Protects Mice against Rotavirus Infection

Parez

Fourgeux

Mohamed

et al. 2006

J Virol

View full text Add to dashboard Cite

show abstract

“…In 2006, two new oral rotavirus vaccines were released onto the market: Rotarix ® – a live monovalent attenuated human strain by GlaxoSmithKline Biologicals (Vesikari et al, 2004; Keating, 2006b) and RotaTeq ® – a live pentavalent human-bovine reassortant vaccine by Merck & Co. Inc. (Clark et al, 2004; Keating, 2006a). After 6 years of use, a Cochrane Review found that both of these vaccines are efficacious with no increased risk of adverse side effects such as intussusception (Soares-Weiser et al, 2012).…”

Section: A Brief History Of Vaccinationmentioning

confidence: 99%

The dichotomy of pathogens and allergens in vaccination approaches

Baird

Lopata

2014

Front. Microbiol.

View full text Add to dashboard Cite

Traditional prophylactic vaccination to prevent illness is the primary objective of many research activities worldwide. The golden age of vaccination began with an approach called variolation in ancient China and the evolution of vaccines still continues today with modern developments such as the production of GardasilTM against HPV and cervical cancer. The historical aspect of how different forms of vaccination have changed the face of medicine and communities is important as it dictates our future approaches on both a local and global scale. From the eradication of smallpox to the use of an experimental vaccine to save a species, this review will explore these successes in infectious disease vaccination and also discuss a few significant failures which have hampered our efforts to eradicate certain diseases. The second part of the review will explore designing a prophylactic vaccine for the growing global health concern that is allergy. Allergies are an emerging global health burden. Of particular concern is the rise of food allergies in developed countries where 1 in 10 children is currently affected. The formation of an allergic response results from the recognition of a foreign component by our immune system that is usually encountered on a regular basis. This may be a dust-mite or a prawn but this inappropriate immune response can result in a life-time of food avoidance and lifestyle restrictions. These foreign components are very similar to antigens derived from infectious pathogens. The question arises: should the allergy community be focussing on protective measures rather than ongoing therapeutic interventions to deal with these chronic inflammatory conditions? We will explore the difficulties and benefits of prophylactic vaccination against various allergens by means of genetic technology that will dictate how vaccination against allergens could be utilized in the near future.

show abstract

“…1). 31 Therefore, it was of interest to ascertain whether a "mirror image" single-gene WC3 reassortant constructed to contain the P1 VP4 antigen of WI79 virus would induce a predominant SNA response to the human WI79 P1 rotavirus and a lesser response to bovine WC3 G6 rotavirus. A single reassortant (WI79-4 G6P1) and a double reassortant (WI79-4 ϩ 9 G1P1) were produced and tested.…”

Section: Inclusion Of the Vp4 (P1) Component In An Infant Rotavirusmentioning

confidence: 99%

“…1). 31 The addition of a human G1 protein to WC3 converted a WC3 vaccine that was sporadically effective to a G1 reassortant that was consistently protective.…”

mentioning

confidence: 99%

The New Pentavalent Rotavirus Vaccine Composed of Bovine (Strain WC3) -Human Rotavirus Reassortants

Clark

Offit²,

Plotkin³

et al. 2006

Pediatric Infectious Disease Journal

Self Cite

View full text Add to dashboard Cite

show abstract

Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: different dose response patterns to virus surface proteins VP7 and VP4

Abstract: Two doses of G1 reassortant WI79 were necessary to induce significant antibody responses to human G1 (VP7) antigen in >50% of infants. Three doses were required to achieve significant antibody responses to VP7 in >70% of infants.

Cited by 18 publications

References 16 publications

Rectal Immunization with Rotavirus Virus-Like Particles Induces Systemic and Mucosal Humoral Immune Responses and Protects Mice against Rotavirus Infection

Rectal Immunization with Rotavirus Virus-Like Particles Induces Systemic and Mucosal Humoral Immune Responses and Protects Mice against Rotavirus Infection

The dichotomy of pathogens and allergens in vaccination approaches

The New Pentavalent Rotavirus Vaccine Composed of Bovine (Strain WC3) -Human Rotavirus Reassortants

Contact Info

Product

Resources

About